Indivumed announces collaboration utilizing Aptila’s proteomics expertise
We are excited to collaborate with Aptila Biotech, a leader in DIA proteomics software. With the DIA-NN software included in our comprehensive target discovery process, we can further optimize our data for deep proteomics analysis, providing unparalleled molecular insights that are critical for our novel therapeutic discovery.
Indivumed is pleased to announce a close working relationship with Aptila as of August 2025. Aptila’s software suite, DIA-NN, is a leading solution for data-independent acquisition (DIA) proteomics. This collaboration represents an additional advancement in Indivumed's novel target discovery approaches. By leveraging the innovative capabilities of DIA-NN, Indivumed aims to enhance the precision and effectiveness of their R&D, specifically in proteomics analysis.
Indivumed's unique and standardized tissue collection process results in high quality multi-omics raw data, including proteomics and phospho-proteomics. When combined with longitudinal clinical data, this builds the basis for their patient-centric R&D approach.
With the DIA-NN software included in their comprehensive target discovery process, Indivumed can further optimize their data resource for deep proteomics analysis, providing unparalleled molecular insights that are critical for oncology therapeutic discovery.
This exciting opportunity combines both company’s strengths to make meaningful advancements in cancer research.
About Aptila:
Aptila specializes in LC-MS proteomics, offering a streamlined software solution that ensures data reliability and quantitative accuracy. Aptila’s DIA-NN serves as the foundation for multiple DIA technologies, such as plexDIA and QuantUMS. Aptila's expertise allows for a detailed examination of the proteome and its role in driving disease.
About Indivumed:
Indivumed is a biotech company focused on precision oncology. We discover therapeutically novel targets for the development of precision cancer therapeutics and strive for a future where every cancer patient can benefit from precise therapeutic treatments. To achieve this goal, we dedicate our skills and knowledge in cancer research to the identification, validation, and preclinical development of first-in-class therapeutics. With more than twenty years of experience and a truly unique resource based on a standardized collection process that secures a cold ischemia time of under 10 minutes, we are committed to transforming oncology and bringing the best possible therapies to patients.
For more information about our collaboration, please visit indivumed.com and aptila.bio.